Clinical trial finds RNA inhibitor effectively reduces 'bad cholesterol' in patients with cardiovascular disease
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...
Business Wire6d
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025
AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...
Nature6d
Mechanisms of Disease: histone modifications in Huntington's disease
Furthermore, recent studies have shown a therapeutic role for histone deacetylase inhibitors in a number of ... afflicts around one in 10,000 people. 1 HD onset typically occurs in young adult ...
pharmaphorum2d
Opdivo's subcutaneous PD-1 inhibitor cleared in US
It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...
El Mundo on MSN2d
US approves a new painkiller with less risk of addiction than opioids and equally potent
The suzetrigine, which only acts on pain neurons, is the first innovation in analgesia in the last 20 years. "It stands out ...
eLife4d
Sphingosine-1-phosphate signaling regulates the ability of Müller glia to become neurogenic, proliferating progenitor-like cells
Convincing evidence shows that the sphingosine-1-phosphate (S1P) signaling pathway is inhibited following retinal injury. Small-molecule activators and inhibitors support a model in which S1P ...